Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822590 | PMC |
| http://dx.doi.org/10.1002/cac2.12242 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Acid sphingomyelinase activity suggests a new antipsychotic pharmaco-treatment strategy for schizophrenia.
Mol Psychiatry
January 2025
Department of Psychiatry and Psychotherapy, University Clinic, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany.
Schizophrenia is a chronic and severe mental disorder. It is currently treated with antipsychotic drugs (APD). However, APD's work only in a limited number of patients and may have cognition impairing side effects.
View Article and Find Full Text PDFInhibition of prefrontal glutamatergic neuron activity during the recovery period following chronic stress disrupts fear memory in male rats: potential role of the infralimbic cortex.
Learn Mem
January 2025
Department of Psychology, Arizona State University, Tempe, Arizona 85287, USA
Chronic stress typically leads to deficits in fear extinction. However, when a delay occurs from the end of chronic stress and the start of fear conditioning (a "recovery"), rats show improved context-cue discrimination, compared to recently stressed rats or nonstressed rats. The infralimbic cortex (IL) is important for fear extinction and undergoes neuronal remodeling after chronic stress ends, which could drive improved context-cue discrimination.
View Article and Find Full Text PDFPsychopathology trajectories and relapse in first episode schizophrenia with assured long-acting injectable adherence over 24 months.
Schizophr Res
January 2025
Faculty of Medicine and Health Sciences, Department of Psychiatry, Stellenbosch University, Tygerberg, 7500 Cape Town, South Africa.
Background: Relapse following a first episode of schizophrenia (FES) is common and often results in serious adverse psychosocial consequences. Treatment non-adherence is a key risk factor for relapse, but why relapse occurs despite antipsychotic treatment adherence remains unclear. This study examined the differences in FES psychopathology trajectories over 24-months with assured long-acting injectable antipsychotic (LAIA) treatment, to control for treatment adherence between those who relapsed and those who did not and what moderates these group differences.
View Article and Find Full Text PDFLong-acting Injectable Aripiprazole (Abilify Maintena) Induced Rabbit Syndrome: A Case Report and Review of the Literature.
Clin Psychopharmacol Neurosci
February 2025
Department of Psychiatry, Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwan.
Rabbit syndrome (RS), characterized by fine, rapid, rhythmic movements along the mouth's vertical axis, is typically linked to prolonged antipsychotic medication use. Emerging evidence suggests newer antipsychotics' involvement in RS, prompting investigation into its association with long-acting injectable antipsychotics (LAIs) for schizophrenia or bipolar disorder. We report a case of RS observed in a patient diagnosed with bipolar I disorder and treated with Abilify Maintena, highlighting the importance of vigilance in monitoring adverse effects.
View Article and Find Full Text PDFXanomeline-trospium (Cobenfy) for Schizophrenia: A Review of the Literature.
Clin Psychopharmacol Neurosci
February 2025
Department of Pharmacy Practice, Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC, USA.
Schizophrenia is a chronic and severe mental illness associated with substantial morbidity and mortality. Antipsychotics primarily rely on direct dopamine blockade, leading to potential life-interfering adverse events. The purpose of this review is to describe the safety and efficacy of xanomeline-trospium (Cobenfy), a Food and Drug Administration approved treatment for schizophrenia in adults.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!